Actinium Pharmaceuticals Inc (ATNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $51.56M
Last updated: Nov 17, 2026 at 11:04 AM ET
Actinium Pharmaceuticals Inc (ATNM) Earnings: Report Dates and Results
Actinium Pharmaceuticals (ATNM) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Actinium Pharmaceuticals reported EPS of $0.89, above the -$0.20 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ATNM has an expected report date of Mar 29, 2027.
Earnings History
Of the 40 quarters below that had an estimate, ATNM beat 24, missed 11 and matched 5. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 545.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | $0.89 | -$0.20 | -$0.20 - -$0.20 | +545.00% | Beat | N/A | 1 | 2 up, 0 down | Aug 7, 2026 | $35.00M |
| Mar 31, 2026 | -$0.18 | -$0.22 | -$0.22 - -$0.22 | +18.18% | Beat | N/A | 3 | 0 up, 1 down | May 8, 2026 | N/A |
| Dec 31, 2025 | -$0.19 | -$0.18 | -$0.20 - -$0.17 | -5.78% | Miss | N/A | 3 | 2 up, 1 down | Mar 30, 2026 | N/A |
| Sep 30, 2025 | -$0.16 | -$0.32 | -$0.48 - -$0.24 | +50.00% | Beat | N/A | 3 | 1 up, 0 down | Nov 14, 2025 | $90000 |
| Jun 30, 2025 | -$0.22 | -$0.35 | -$0.46 - -$0.30 | +37.14% | Beat | N/A | 4 | 0 up, 2 down | Aug 8, 2025 | N/A |
| Mar 31, 2025 | -$0.51 | -$0.28 | -$0.35 - -$0.24 | -82.14% | Miss | N/A | 4 | 0 up, 0 down | May 9, 2025 | N/A |
| Dec 31, 2024 | -$0.21 | -$0.39 | -$0.44 - -$0.29 | +46.15% | Beat | N/A | 4 | 0 up, 3 down | Mar 31, 2025 | $810000 |
| Sep 30, 2024 | -$0.37 | -$0.37 | -$0.40 - -$0.25 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$0.38 | -$0.40 | -$0.58 - -$0.31 | +5.00% | Beat | N/A | 6 | 0 up, 0 down | Aug 5, 2024 | N/A |
| Mar 31, 2024 | -$0.31 | -$0.52 | -$0.65 - -$0.42 | +40.38% | Beat | N/A | 3 | 1 up, 0 down | Apr 26, 2024 | N/A |
| Dec 31, 2023 | -$0.33 | -$0.54 | -$0.61 - -$0.48 | +38.89% | Beat | N/A | 5 | 0 up, 0 down | Mar 29, 2024 | $81000 |
| Sep 30, 2023 | -$0.49 | -$0.57 | -$0.73 - -$0.38 | +14.04% | Beat | N/A | 6 | 1 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$0.58 | -$0.49 | -$0.58 - -$0.44 | -18.37% | Miss | N/A | 5 | 0 up, 0 down | Aug 14, 2023 | N/A |
| Mar 31, 2023 | -$0.43 | -$0.43 | -$0.47 - -$0.37 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Apr 3, 2023 | N/A |
| Dec 31, 2022 | -$0.43 | -$0.35 | -$0.43 - -$0.09 | -22.86% | Miss | N/A | 6 | 0 up, 0 down | Mar 31, 2023 | N/A |
| Sep 30, 2022 | -$0.38 | -$0.31 | -$0.35 - -$0.22 | -22.58% | Miss | N/A | 6 | 1 up, 0 down | Nov 14, 2022 | $45000 |
| Jun 30, 2022 | -$0.33 | -$0.23 | -$0.28 - $1.29 | -43.48% | Miss | N/A | 2 | 0 up, 0 down | Aug 12, 2022 | $90000 |
| Mar 31, 2022 | -$0.23 | -$0.31 | -$0.36 - -$0.26 | +25.81% | Beat | N/A | 4 | 0 up, 0 down | May 13, 2022 | $1.88M |
| Dec 31, 2021 | -$0.36 | -$0.30 | -$0.34 - -$0.26 | -20.00% | Miss | N/A | 4 | 0 up, 0 down | Mar 25, 2022 | $1.17M |
| Sep 30, 2021 | -$0.30 | -$0.28 | -$0.28 - -$0.28 | -7.14% | Miss | N/A | 2 | 0 up, 0 down | Nov 12, 2021 | $233000 |
| Jun 30, 2021 | -$0.25 | -$0.29 | -$0.34 - -$0.25 | +13.79% | Beat | N/A | 4 | N/A | Jul 30, 2021 | $266000 |
| Mar 31, 2021 | -$0.29 | -$0.34 | -$0.35 - -$0.19 | +14.71% | Beat | N/A | 3 | N/A | May 14, 2021 | $622000 |
| Dec 31, 2020 | -$0.37 | -$0.37 | -$0.44 - -$0.24 | 0.00% | In line | N/A | 5 | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | -$0.36 | -$0.46 | -$0.59 - -$0.33 | +21.74% | Beat | N/A | 4 | N/A | Oct 23, 2020 | N/A |
| Jun 30, 2020 | -$0.41 | -$0.40 | -$0.60 - -$0.30 | -2.50% | Miss | N/A | 3 | N/A | Aug 14, 2020 | N/A |
| Mar 31, 2020 | -$0.90 | -$1.20 | -$1.20 - -$0.30 | +25.00% | Beat | N/A | 3 | N/A | May 8, 2020 | N/A |
| Dec 31, 2019 | -$0.90 | -$1.20 | -$1.20 - -$1.20 | +25.00% | Beat | N/A | 3 | N/A | Mar 13, 2020 | N/A |
| Sep 30, 2019 | -$1.20 | -$1.20 | -$1.20 - -$0.90 | 0.00% | In line | N/A | 3 | N/A | Nov 12, 2019 | N/A |
| Jun 30, 2019 | -$0.90 | -$1.50 | -$1.50 - -$0.90 | +40.00% | Beat | N/A | 3 | N/A | Aug 9, 2019 | N/A |
| Mar 31, 2019 | -$1.50 | -$1.70 | -$1.80 - -$1.50 | +11.76% | Beat | N/A | 3 | N/A | May 10, 2019 | N/A |
| Dec 31, 2018 | -$1.50 | -$1.80 | N/A | +16.67% | Beat | N/A | N/A | N/A | Mar 19, 2019 | N/A |
| Sep 30, 2018 | -$1.80 | -$1.35 | N/A | -33.33% | Miss | N/A | N/A | N/A | Nov 9, 2018 | N/A |
| Jun 30, 2018 | -$1.20 | -$1.90 | -$2.10 - -$1.80 | +36.84% | Beat | N/A | 4 | N/A | Aug 9, 2018 | N/A |
| Mar 31, 2018 | -$2.10 | -$2.70 | N/A | +22.22% | Beat | N/A | 3 | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$1.80 | -$2.62 | -$3.00 - -$2.40 | +31.30% | Beat | N/A | 4 | N/A | Mar 16, 2018 | N/A |
| Sep 30, 2017 | -$2.70 | -$2.70 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 3, 2017 | N/A |
| Jun 30, 2017 | -$3.60 | -$4.05 | N/A | +11.11% | Beat | N/A | N/A | N/A | Aug 4, 2017 | N/A |
| Mar 31, 2017 | -$4.20 | -$3.90 | N/A | -7.69% | Miss | N/A | N/A | N/A | May 15, 2017 | N/A |
| Dec 31, 2016 | -$3.60 | -$4.20 | N/A | +14.29% | Beat | N/A | N/A | N/A | Mar 16, 2017 | N/A |
| Sep 30, 2016 | -$4.20 | -$4.95 | N/A | +15.15% | Beat | N/A | N/A | N/A | Oct 28, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.08, after -$1.27 the year before. It was -$15.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.08 | N/A |
| Dec 31, 2024 | -$1.27 | N/A |
| Dec 31, 2023 | -$1.83 | N/A |
| Dec 31, 2022 | -$1.37 | N/A |
| Dec 31, 2021 | -$1.20 | N/A |
| Dec 31, 2020 | -$2.04 | N/A |
| Dec 31, 2019 | -$4.50 | N/A |
| Dec 31, 2018 | -$6.60 | N/A |
| Dec 31, 2017 | -$12.30 | N/A |
| Dec 31, 2016 | -$15.30 | N/A |
Frequently Asked Questions About ATNM
When is Actinium Pharmaceuticals's next earnings date?
Actinium Pharmaceuticals's next earnings report is expected for Mar 29, 2027.
Did ATNM beat earnings estimates last quarter?
Yes. Actinium Pharmaceuticals reported EPS of $0.89 for the quarter ended Jun 30, 2026, above the -$0.20 estimate, a 545.00% surprise.
What EPS do analysts expect from ATNM next quarter?
The consensus EPS estimate for Actinium Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.24 from 5 analysts, with estimates from -$0.31 to -$0.15.
How often does ATNM beat earnings estimates?
Actinium Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +76.07%.
ATNM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors